Skip to content

taVNS Reduces Postoperative Pain and Complications in Patients With Gastric and Intestinal Tumors

taVNS Reduces Postoperative Pain and Complications in Patients With Gastric and Intestinal Tumors: A Randomized, Double-Blind, Parallel-Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06763913
Acronym
taVNS
Enrollment
80
Registered
2025-01-08
Start date
2025-01-01
Completion date
2025-07-30
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

taVNS, Gastrointestinal Tumor Surgery, Visual Analogue Scale, Complications

Keywords

taVNS, Perioperative period, Visual Analogue Scale, complications

Brief summary

Postoperative acute pain control in patients with gastrointestinal tumors is not satisfactory, and surgical complications including gastrointestinal dysfunction, gastrointestinal fistula, abdominal and gastrointestinal hemorrhage, peritonitis and abscess, are still important factors affecting surgical outcomes, postoperative recovery, hospital stay, and even perioperative mortality. The application of taVNS during the perioperative period can enhance or preserve vagal nerve function, which may protect important organ functions through multiple pathways such as alleviating pain and inflammatory responses caused by surgical trauma, improving gastrointestinal function, enhancing cardiovascular regulation, reducing postoperative nausea and vomiting, and accelerating postoperative recovery, thereby reducing postoperative complications and mortality.

Detailed description

Subjects who met the inclusion criteria were enrolled in the clinical trial and received 2 interventions at the following times: the day before surgery, and the afternoon of the 1st day postoperatively (15:00-17:00), a total of 2 times. The intervention implementers used vagus nerve stimulation equipment to place electrodes in the tragus area of the outer ear of the subjects in the experimental group (taVNS group). The control group (sham stimulation group) was set to have a pulse width of 200 μs, a frequency of 1 Hz, and an initial current of 10 mA, which was gradually increased to the pain tolerance threshold of the subject, capped at 50 mA,last for one hour. The VAS scores before and after stimulation for 10 minutes were recorded. 2\) ECG monitoring: Both groups were monitored with a dynamic ECG monitor during the intervention period, starting 10 minutes before stimulation and ending 10 minutes after stimulation. The SDNN (Standard Deviation of NN intervals) of the sinus rhythm was measured before and after stimulation for 10 minutes. A uniform standard was used for anesthesia induction and maintenance during surgery, and all patients used the same patient-controlled intravenous analgesia (PCIA) plan.

Interventions

DEVICEtaVNS

Set the pulse width to 200 microseconds, frequency to 30 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA,last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.

Set the pulse width to 200 microseconds, frequency to 1 Hz, and start the current at 10 mA. Gradually increase the current until the patient reaches their pain tolerance threshold, and cap it at 50 mA,last for one hour.During the intervention, dynamic ECG monitoring was conducted using an ECG monitor, starting 10 minutes before the stimulation and ending 10 minutes after the stimulation.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Age 18-80 years, BMI 18-30 kg/m², ASA Ⅱ-Ⅲ, elective laparoscopic gastric or intestinal tumor surgery, expected surgical duration ≥2 hours, patient understands study content and signs informed consent form.

Exclusion criteria

Kidney replacement therapy, treatment for arrhythmias requiring treatment, dementia, severe bradycardia, orthostatic tachycardia syndrome, neuro-muscular disorders, auricular dermatitis, planned post-operative transfer to ICU

Design outcomes

Primary

MeasureTime frameDescription
Difference in VAS Score on Postoperative Day 1before and after each stimulus for 10 minutesDifference in VAS Score on Postoperative Day 1

Secondary

MeasureTime frameDescription
Postoperative Complication Rate1 day before being discharged from the hospitalPostoperative in-hospital complication rate
The time of the first postoperative anal exhaustOn the third day after the operationThe time of the first postoperative anal exhaust
The effective number of pain relief pump pressesOne day before being discharged from the hospitalThe effective number of pain relief pump presses
The QoR-15 scale scores on the 1st and 3rd days after surgery1 day before the operation and the third day after the operationThe QoR-15 scale scores on the 1st and 3rd days after surgery
Length of hospital stayOne day before being discharged from the hospitalLength of hospital stay
Standard Deviation of NN intervals10 minutes before and after each stimulus10 minutes before and after each stimulus
Root Mean Square of the Successive Differences10 minutes before and after each stimulus10 minutes before and after each stimulus
Postoperative Salvage Analgesic Consumption of Opioid EquivalentsOne day before being discharged from the hospitalPostoperative Salvage Analgesic Consumption of Opioid Equivalents

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026